July 26, 2014 5:49 AM ET

Pharmaceuticals

Company Overview of Inotek Pharmaceuticals Corporation

Company Overview

Inotek Pharmaceuticals Corporation develops drug candidates to address significant diseases of the eye. The company specializes in developing molecules with novel mechanisms of action to fulfill unmet medical needs in significant diseases of the eye. Its product INO-8875 is an Adenosine-1 receptor agonist and potential eye-drop product for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. The company’s products also include polymerase inhibitors and superoxide dismutase mimetics that alleviate oxidative injury and inflammation for medical needs in retinal diseases. Inotek Pharmaceuticals Corporation was formerly known as Inotek Corpor...

33 Hayden Avenue

2nd Floor

Lexington, MA 02421

United States

Founded in 1996

Phone:

978-232-9660

Fax:

978-232-8975

Key Executives for Inotek Pharmaceuticals Corporation

Chief Executive Officer
Age: 59
Executive Chairman
Age: 64
Chief Financial Officer
Age: 64
Chief Medical Officer and Executive Vice President
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Inotek Pharmaceuticals Corporation Key Developments

Inotek Pharmaceuticals Announces Study Results Demonstrating Neuroprotective Properties of Trabodenoson

Inotek Pharmaceuticals Corporation announced the results from a preclinical study demonstrating the ability of trabodenoson, an adenosine A1 mimetic in development for glaucoma, to protect against the loss of retinal ganglion cells in an acute high-ocular-pressure animal model of glaucoma. Retinal ganglion cells are the part of the nervous system responsible for relaying the visual image from the eye to the brain, and their death is what causes the irreversible vision loss associated with glaucoma. The results of this study were presented this month at the 2014 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). This preclinical neuroprotection study was designed to compare the protective effects of trabodenoson and brimonidine in a rat model of ischemia-induced retinal ganglion cell (RGC) death. Trabodenoson was delivered as an eye drop at a clinically relevant dose. Results of the study showed that trabodenoson provided 100% protection against the thinning of the ganglion cell layer (p<=0.001 compared to vehicle-treated eyes).

Inotek Pharmaceuticals Initiates Phase 2 Study with Trabodenoson in Combination with Latanoprost for Patients with Glaucoma or Ocular Hypertension

Inotek Pharmaceuticals Inc. announced the initiation of a Phase 2 clinical study of its lead product, trabodenoson, in combination with the most widely-prescribed glaucoma drug, the prostaglandin analog latanoprost (LAT), in patients with elevated intraocular pressure (IOP) that remains uncontrolled despite ongoing treatment with latanoprost. The Phase 2 study is a randomized, double-masked, active-controlled, multicenter trial comparing trabodenoson plus LAT, to timolol (the active comparator) plus LAT, in 120 patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG). The study will measure the additive or synergistic IOP lowering effect of trabodenoson when combined with LAT, and will also evaluate the safety and tolerability of the combined treatment regimen. The total treatment time will be 3 months, during which the effect of trabodenoson will be evaluated following twice-a-day dosing (BID) and once-daily dosing (QD). Top line data is expected in the fourth quarter of 2014.

Inotek Pharmaceuticals Corp. Closes $21 Million Financing

Inotek Pharmaceuticals Corp. announced that it has closed on a $21 million financing. According to a release, proceeds from this financing will be used to advance Inotek's lead product, trabodenoson, a novel eye drop that increases aqueous fluid outflow via the eye's trabecular meshwork, through phase 2 studies in glaucoma.

Similar Private Companies By Industry

Company Name Region
ChanRx Corp. United States
P3 Laboratories, LLC United States
Lundbeck Inc. United States
Orphan Medical Inc. United States
Zindol, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Inotek Pharmaceuticals Corporation, please visit www.inotekcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.